Literature DB >> 24612600

Targeting CCR4 as an emerging strategy for cancer therapy and vaccines.

Jagadeesh Bayry1, Eric Tartour2, David F Tough3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24612600     DOI： 10.1016/j.tips.2014.02.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  14 in total

1.  Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.

Authors:  Sima Velashjerdi Farahani; Mohammad Reza Aghasadeghi; Arash Memarnejadian; Sobhan Faezi; Zahra Shahosseini; Mehdi Mahdavi
Journal:  Pathog Glob Health       Date:  2016-04-13       Impact factor: 2.894

Review 2.  Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

Review 3.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

4.  Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.

Authors:  Zhaohui Wang; Min Wei; Huiping Zhang; Hongyuan Chen; Sharon Germana; Christene A Huang; Joren C Madsen; David H Sachs; Zhirui Wang
Journal:  Mol Oncol       Date:  2015-04-25       Impact factor: 6.603

5.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

6.  Regulatory T Cells Modulate DNA Vaccine Immunogenicity at Early Time via Functional CD4(+) T Cells and Antigen Duration.

Authors:  Lizeng Qin; Guosheng Jiang; Jinxiang Han; Norman L Letvin
Journal:  Front Immunol       Date:  2015-09-29       Impact factor: 7.561

7.  Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination.

Authors:  Iris Bosschem; Jagadeesh Bayry; Ellen De Bruyne; Kim Van Deun; Annemieke Smet; Griet Vercauteren; Richard Ducatelle; Freddy Haesebrouck; Bram Flahou
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

Review 8.  Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection.

Authors:  Torben Knuschke; Olga Rotan; Wibke Bayer; Viktoriya Sokolova; Wiebke Hansen; Tim Sparwasser; Ulf Dittmer; Matthias Epple; Jan Buer; Astrid M Westendorf
Journal:  Retrovirology       Date:  2016-04-14       Impact factor: 4.602

9.  Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody.

Authors:  Kenji Sugata; Jun-Ichirou Yasunaga; Michi Miura; Hirofumi Akari; Atae Utsunomiya; Kisato Nosaka; Yuko Watanabe; Hitoshi Suzushima; Ki-Ryang Koh; Masanori Nakagawa; Michinori Kohara; Masao Matsuoka
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

10.  RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo.

Authors:  Lorenz Fülle; Nancy Steiner; Markus Funke; Fabian Gondorf; Franziska Pfeiffer; Julia Siegl; Friederike V Opitz; Silvana K Haßel; Anna Belen Erazo; Oliver Schanz; H James Stunden; Michael Blank; Carsten Gröber; Kristian Händler; Marc Beyer; Heike Weighardt; Eicke Latz; Joachim L Schultze; Günter Mayer; Irmgard Förster
Journal:  Mol Ther       Date:  2017-10-13       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.